Abstract
The SIN3A–HDAC (histone deacetylase) complex is a master transcriptional repressor, required for development but often deregulated in disease. Here, we report that the recently identified new component of this complex, SINHCAF (SIN3A and HDAC-associated factor)/FAM60A (family of homology 60A), links the SIN3A–HDAC co-repressor complex function to the hypoxia response. We show that SINHCAF specifically represses HIF-2α mRNA and protein expression, via its interaction with the transcription factor SP1 (specificity protein 1) and recruitment of HDAC1 to the HIF-2α promoter. SINHCAF control over HIF-2α results in functional cellular changes in in vitro angiogenesis and viability. Our analysis reveals an unexpected link between SINHCAF and the regulation of the hypoxia response.
Keywords: HIF-2histone deacetylases, hypoxia, hypoxia-inducible factors, SIN3A, SP1, transcription
Introduction
SINHCAF [SIN3A and HDAC (histone deacetylase)-associated factor, HUGO nomenclature]/FAM60A (family of homology 60A) is a poorly characterized protein that was originally shown to be part of the SIN3A repressor complex by two independent studies [1,2]. SIN3A is a multi-protein complex with function in developmental processes such as stem cell function [3] but also in pathological processes such as cancer [4]. It controls cellular metabolism, cell cycle, and cell survival [4]. Despite limited knowledge on SINHCAF function, a recent study identified a single-nucleotide polymorphism present on SINHCAF which is associated with type II diabetes in a cohort of Japanese patients [5]. SINHCAF has been associated with eosophageal cancer, by an integrative analysis of copy number [6], and more recently shown to control SIN3A loading in many important genes for stem cell maintenance in mouse embryonic stem cells [7].
Solid tumors are often characterized by the presence of low oxygen or hypoxia [8]. Adaptation and survival to such environments is mediated by a family of transcription factors called hypoxia-inducible factors (HIFs). Transcriptional target genes that are controlled by the HIFs code for proteins that are involved in important cellular processes including energy homeostasis, migration, and differentiation [9–11]. Deregulation of the HIF system has been shown to be important in the development of multiple disease processes including cancer progression and stem cell differentiation [12,13].
HIF is a heterodimeric transcription factor that consists of a constitutively expressed HIF-1β subunit and an O2-regulated HIF-α subunit [14]. Three isoforms of HIF-α have been identified (HIF-1α, -2α, and -3α). The HIF-α isoforms are all characterized by the presence of bHLH (basic helix–loop–helix)–PAS [Per/ARNT (aryl hydrocarbon nuclear translocator)/Sim] and ODD (oxygen-dependent degradation) domains. Both HIF-1α and HIF-2α have important cellular functions as transcription factors with some redundancy in their targets [15,16]. HIF-2α protein shares sequence similarity and functional overlap with HIF-1α, but its distribution is restricted to certain cell types, and in some cases, it mediates distinct biological functions [17].
The regulation of the HIF-α subunits is best understood at the post-transcriptional level and is mediated by hydroxylation-dependent proteasomal degradation. In well-oxygenated cells, HIF-α is hydroxylated in its ODD. This proline hydroxylation is catalyzed by a class of dioxygenase enzymes called prolyl hydroxylases (PHDs). PHDs require Fe2+ and α-ketoglutarate as cofactors for their catalytic activity, and have an absolute requirement for molecular oxygen as a co-substrate, making their activity reduced in hypoxia [18–21]. Prolyl-hydroxylation of HIF-α attracts the von Hippel–Lindau (vHL) tumor suppressor protein, which recruits the Elongin C–Elongin B–Cullin 2–E3–ubiquitin–ligase complex, leading to the Lys48-linked polyubiquitination and proteasomal degradation of HIF-α [22–24]. In hypoxia, HIF-α is stabilized, can form a heterodimer with HIF-1β in the nucleus, and bind to the consensus cis-acting hypoxia-response element (HRE) nucleotide sequence 5′-RCGTG-3′, which is present within the enhancers and/or promoters of HIF target genes [25–27]. HIF-α stabilization therefore allows the cell to enact a transcriptional program that is appropriate to the hypoxic environment [28].
In contrast with the post-translation regulation of HIF, the factors that regulate the basal expression of the HIF-α isoforms are only now being investigated. Deregulation of HIF basal expression has been linked to the development of solid tumors [29]. The transcriptional regulator nuclear factor kappaB (NF-κB) is a direct modulator of HIF-1α expression, in basal and hypoxic conditions, as well as in response to inflammatory stimulus [21,30–33]. NF-κB also directly regulates HIF-1β mRNA and protein levels, resulting in modulation of HIF-2α protein levels by preventing protein degradation [34,35]. Additional studies have also shown that SP1 (specificity protein 1)/3 and Egr-1 transcription factors and the STAT3 transcriptional activator can all regulate expression of HIF 1α RNA [36–41]. HIF-2α can be regulated by SP1/3 in 3T3-L1 mouse embryonic cells during adipocyte differentiation [42] and during cell progression by E2F1 in cancer [43]. Interestingly, HIF-2α has recently been shown to be sensitive to histone deacetylase (HDAC) inhibition in soft tissue sarcomas [44]. HDACs are components of several transcriptional repressor complexes, including the SIN3A complex [4].
Here, we show that SINHCAF links SIN3A function to hypoxia signaling. SINHCAF targets the HIF-2α promoter, resulting in histone deacetylation and gene silencing. SINHCAF is maintained at the HIF-2α promoter by the transcription factor SP1. Interestingly, SINHCAF is also required for optimal retention of SP1 at the HIF-2α promoter. Finally, SINHCAF and HIF-2α functions are inversely correlated in an in vitro angiogenesis assay and in the control of cellular viability/proliferation.
Materials and methods
Cell culture and treatments
All cell lines were maintained for no more than 30 passages and grown in Dulbecco's modified Eagle's medium or Roswell Park Memorial Institute medium containing 1% penicillin and streptomycin, supplemented with 10% fetal bovine serum (Sigma). Hypoxic treatments were 1% O2 unless otherwise stated and delivered using a Baker-Ruskinn InVivo2 300 hypoxia chamber. MG132 (Merck/Millipore) was dissolved in DMSO added for 6 h at final concentration of 10 µM. TSA (Trichostatin A; NEB, U.K.) was added to cells where indicated for 6 h at final concentration of 400 nM. Serum response experiments were performed as described in ref. [43]. Briefly, cells were transfected as described below, 24 h later, media were changed to low serum (0.5%) for an additional 24 h. Where indicated, full media (10%) were added for an additional 6 h prior to lysis.
Small interfering RNA and plasmid transfection
Small interfering RNA (siRNA) transfections were performed using Interferin (Peqlab), and DNA transfections using TurboFect (Thermo). All reagents were used according to the manufacturer's instructions. SINHCAF expression constructs were described in ref. [1]. HIF-2α promoter fused to renilla luciferase construct was obtained from GeneCopoeia.
siRNA sequences
Control, CAG UCG CGU UUG CGA CUG G [45]; HIF-2α, CAG CAU CUU UGA CAG U [45]; SINHCAF_1, CAG UAA ACU GCA GAA GGA A [1]; SINHCAF_2, GUC AGA UGA CGG CUC AGA U [1]; PHD2, GACGAAAGCCAUGGUUGCUUG [46]; E2F1, CGC UAU GAG ACC UCA CUG [47]; NFKB2, CAG CCU AAG CAG AGA GGC U [48]; SP1, CCU GGA GUG AUG CCU AAU A [49]; SP3, AGA CGA AGC UGG UAA UCU A; SIN3A, GGU CUA AGA GCU UAC UCA A [1]; HDAC1, GUU AGG UUG CUU CAA UCU A [1].
Integrative analysis using public datasets
Analysis of A549 microarray [2] was performed using the GEO2R tool on the GEO website. The following ChIP (chromatin immunoprecipitation) sequencing datasets from the encode project [50,51] were downloaded from the NCBI GEO database, HeLa S3 RNA Pol II (GSM935395), A549 SIN3A (GSM1010882), and HeLa S3 H3K4me3 (GSM733682). Coverage tracks were generated using the Gvis R Bioconductor package [52].
Immunoblots
Cells were lysed in RIPA buffer, 50 mM Tris–HCl (pH 8), 150 mM NaCl, 1% (v/v) NP40, 0.5% (v/v) Na-deoxycholate, 0.1% (v/v) SDS, and 1 tablet/10 ml Complete, Mini, EDTA-free protease inhibitors (Roche). SDS–PAGE and immunoblots were carried out using standard protocols.
Antibodies were used as follows: SINHCAF [1], HIF-2α (PA1-16510, Thermo Scientific; 7096, Cell Signaling), β-actin (3700, Cell Signaling), HIF-1α (610958, BD Biosciences), HIF-1β (3718, Cell Signaling), PHD2 (Bethyl A300-322A; 4835, Cell Signaling); p52 (05-361, Merck/Millipore), E2F1 (3742, Cell Signaling), SP1 (07-645, Merck/Millipore), SP3 (sc-644, Santa Cruz Biotech), Sin3A (sc-994, Santa Cruz Biotech; 8056, Cell Signaling); HDAC1 (17-10199; Merck/Millipore), AcH3 (acetylated histone H3; 06-599, Merck/Millipore), p62/STQM (610832, BD Biosciences), poly-ADP ribose polymerase (PARP) (9532, Cell Signaling), cleaved PARP (9541, Cell Signaling), caspase-3 (9662, Cell Signaling), cleaved caspase-3 (9661, Cell Signaling), and LC3B (3868, Cell Signaling).
Immunoprecipitation
For immunoprecipitation of endogenous SINHCAF, cells lysed in lysis buffer [10 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1% (v/v) Triton X-100, 20% (v/v) glycerol, and 1 tablet/10 ml Complete, Mini, EDTA-free protease inhibitors (Roche)].
Cleared cell lysate was rotated overnight at 4°C with 2 µg of anti-SINHCAF antibody and then for an additional 1 h 30 min after adding protein G-Sepharose (Generon). Immobilized antigen–antibody complex was then washed three times with PBS and eluted in 20 µl of Laemli (2×SDS buffer) buffer.
Quantitative reverse transcription–polymerase chain reaction
RNA was extracted using the peqGOLD total RNA kit (Peqlab), according to the manufacturer's instructions, and reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen). For quantitative PCR, Brilliant II Sybr green kit (Statagene/Agilent), including specific MX3005P 96-well semi-skirted plates, was used to analyze samples on the MX3005P qPCR platform (Stratagene/Agilent). Actin was used as a normalizing agent in all experiments. The following primers were used for RT–PCR:
Actin: F: 5′-CTGGGAGTGGGTGGAGGC-3′
Actin: R: 5′-TCAACTGGTCTCAAGTCAGTG-3′
HIF-2α: F: 5′-TTTGATGTGGAAACGGATGA-3′
HIF-2α: R: 5′-GGAACCTGCTCTTGCTGTTC-3′
HIF-1α: F: 5′-CAT AAA GTC TGC AAC ATG GAA GGT-3′
HIF-1α: R: 5′-ATT TGA TGG GTG AGG AAT GGG TT-3′
SINHCAF: F: 5′-CCTGTGCCTCCCTTCATATT-3′
SINHCAF: R: 5′-CAGGGTCTTGCCTATCCTAAAG-3′
SP1: F: 5′-ACC AGG CTG AGC TCC ATG AT-3′
SP1: R: 5′-CCT CAG TGC ATT GGG TAC TTC-3′
ChIP-PCR assays
ChIP assays were performed as described previously [48]. Briefly, proteins and chromatin were cross-linked with 1% formaldehyde at room temperature for 10 min. Glycine was added to a final concentration of 0.125 M for 5 min to quench the reaction. Cells were harvested into 400 µl of lysis buffer [1% SDS, 10 mM EDTA, 50 mM Tris–HCl (pH 8.1), 1 mM PMSF, 1 µg/ml leupeptin, and 1 µg/ml aprotinin] and left on ice for 10 min. Samples were then sonicated at 4°C eight times for 15 s with a 30 s gap between each sonication at 50% amplitude (Sonics Vibra-Cell # VCX130). Supernatants were recovered by centrifugation (12 000 rpm for 10 min at 4°C) before 10% of each sample was stored as input. Remaining samples were split into 120 µl aliquots before being diluted 10-fold in dilution buffer [1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and 20 mM Tris–HCl (pH 8.1)]. Diluted samples were pre-cleared for 2 h at 4°C by incubating with 2 µg of sheared salmon sperm DNA and 20 µl of protein G-Sepharose (50% slurry).
Immunoprecipitations were performed overnight on the remaining sample with 2 µg of antibody, with the addition of Brij 35 detergent to a final concentration of 0.1%. Immune complexes were captured by incubation with 40 µl of protein G-Sepharose (50% slurry) and 2 µg of salmon sperm DNA for 1 h at 4°C. The immunoprecipitates were washed sequentially for 5 min each at 4°C in wash buffer 1 [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl (pH 8.1), and 150 mM NaCl], wash buffer 2 [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl (pH 8.1), and 500 mM NaCl], and wash buffer 3 [0.25 M LiCl, 1% Non-idet P-40, 1% deoxycholate, 1 mM EDTA, and 10 mM Tris–HCl (pH 8.1)]. Beads were washed twice with Tris–EDTA buffer and eluted with 120 µl of elution buffer (1% SDS and 0.1 M NaHCO3). Cross-links were reversed by incubation with 0.2 M NaCl at 65°C overnight, and Proteinase K (20 µg each), 40 mM Tris–HCl (pH 6.5), and 10 mM EDTA for 1 h at 45°C were used to remove protein. DNA was purified using a PCR-product purification kit according to the manufacturer's instructions (NBS Biologicals #NBS363). Three microliters of DNA were used for qPCR with the following primers for the HIF-2α promoter.
F: 5′-TCCTCCCAGTCACCTTTCT-3′
R: 5′-TGGTGAAGGTCCGAGGT-3′
qPCR results are expressed relatively to input material, as mean and SEM of a minimum of three independent experiments.
Tube formation assay
Tube formation assays were performed using HUVECs and µ-slides (i-Bidi) as described in ref. [53]. Briefly, 10 µl of Geltrex (Invitrogen) was added to the inner well and allowed to set at 37°C. A total of 6 × 105 HUVECs were suspended in 300 µl media composed of one-third complete Medium200PRF and two-third conditioned media from assay condition. Fifty microliters of this mixture containing 1 × 105 cells were plated in the outer well of the µ-slide. Cells were allowed organize on the recombinant basement membrane by incubation overnight at 37°C prior to images being acquired by microscopy. The number and length of tube branches were calculated using the images acquired in Image J software (NIH).
Colony formation assay
HeLa and DLD-1 cells were transfected with control or SINHCAF, HIF-2α, or a combination of the two siRNAs for 24 h prior to trypsination. Cells were counted and plated on to six-well plates at the density of 5000 or 10 000 cells per well. Cells were allowed to grow for 6 days prior to staining with Crystal Violet. Plates were imaged and colonies counted using Image J.
Proliferation assay
These assays were performed as described in ref. [54]. Briefly, HeLa cells were transfected with control or SINHCAF siRNAs for 24 h prior to trypsination. Cells were counted and plated on to six-well plates at the density of 50 000 cells per well. Cells were counted 24 and 48 h later using a hemocytometer in triplicate. Results are expressed as an average of total cells counts in each day and represent a three independent experiment.
Cell cycle analysis
Cell cycle analysis was performed as described in ref. [43]. Briefly, cells were trypsinized, media and PBS washes collected in the same tube prior to fixation with 70% ethanol. Samples were then frozen at −20°C for a minimum of 1 day. Fixed cells were washed with PBS and stained using the Cell Cycle analysis Kit from Guava (Millipore 4500-0220) and analyzed in a Guava® easycyte HT (Millipore) cytometer.
Statistical analysis
Data analysis was performed using SigmaPlot v.12.0 (Systat Software, Inc., CA, U.S.A.). One-way analysis of variance (ANOVA) with the Holm–Sidak pairwise comparison was used to compare results between the groups, and data are presented as category mean ± standard error of the mean unless otherwise stated. All statistical tests were two-sided and statistical significance denoted as follows: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
Additional experimental procedures
Additional experimental procedures, such as luciferase assays, have been described previously [55].
Results
SINHCAF and SIN3A depletion result in increased HIF-2α levels
SINHCAF has been identified as a component of the SIN3A/HDAC complex [1,2] and to contribute to transcriptional control of Cyclin D1 [1]. Microarray analysis of SINHCAF and SIN3A regulated genes in A549 cells has identified co-regulated genes within the TGF-β signaling pathway [2]. We have further analyzed this dataset and identified HIF-2α (EPAS1), as one of the genes shared by both SINHCAF and SIN3A (Figure 1A). We confirmed this observation by qPCR, using independent siRNAs for SINHCAF and SIN3A (Figure 1B). Interestingly, this regulation was specific for HIF-2α, as levels of HIF-1α were unaltered by SINHCAF depletion or reduced by SIN3A knockdown in A549 cells (Figure 1B). Similar results were also observed when we analyzed HeLa cells (Figure 1C and Supplementary Figure S1A).
To determine if SINHCAF is a novel regulator of HIF-2α protein expression, A549 and HeLa cells were transfected with control or two SINHCAF siRNA oligonucleotides in order to examine the effect of SINHCAF knockdown on the expression of the HIF isoforms (Figure 2A and Supplementary Figure S1B). Knockdown of SINHCAF resulted in an increase in HIF-2α, but not in HIF-1α or HIF-1β protein expression following exposure to hypoxia for 24 h. Similar results were also observed when SIN3A was depleted by siRNA, with elevated levels of HIF-2α occurring in both HeLa and A549 cells (Figure 2B and Supplementary Figure S1C). Given the importance of maintaining the levels of HIF transcription factors, small changes at mRNA and protein levels can result in significant biological effects. This has been demonstrated by our previous work, and that of others, using cancer cells but also the model organism Drosophila melanogaster [11,20,30,33,43,53].
To determine the penetrance of this effect, similar experiments were performed in multiple cell lines. The loss of SINHCAF resulted in significant increases in HIF-2α with little or no change to HIF-1α protein following exposure to hypoxia in breast cancer cells (MDA-MB-231) and two colorectal (SW480, DLD-1) cell lines (Figure 2C). In addition, overexpression of control or SINHCAF cDNA plasmids in cells was performed to determine if gain-of-function experiments would lead to the opposite effect on HIF-2α levels. Overexpression of SINHCAF resulted in a significant decrease in HIF-2α protein following exposure to hypoxia for 24 h in both HeLa and MDA-MB-231 cells, confirming that the siRNA results are not a technical artifact but also the responsiveness of the system (Figure 2D).
Given that our protein analysis has been performed under hypoxic conditions, we next investigated if SINHCAF could control HIF-2α protein levels following different stimuli. To this end, we performed depletion of PHD2, the main regulator of HIF-α isoforms, in the presence or absence of SINHCAF. Both SINHCAF and PHD2 depletion resulted in modest increases in normoxic levels of HIF-2α (Figure 2E and Supplementary Figure S1D). However, when combined, there was no additive or synergistic effect, a puzzling result, which we cannot fully explain. On the other hand, HIF-1α levels were up-regulated in the absence of PHD2, but once again, this effect was lost when both SINHCAF and PHD2 were depleted (Figure 2E).
To further investigate the effects of SINHCAF in the control of normoxic HIF-2α, we next investigated how SINHCAF alters the levels of HIF-2α in response to serum starvation/addition (Figure 2F). We have previously shown that HIF-2α mRNA levels do increase in response to serum addition [43]. To be able to fully visualize normoxic HIF-2α, we also included the addition of MG132 to cells, prior to lysis. This analysis revealed that SINHCAF depletion does result in increased levels of HIF-2α protein, in normoxic conditions but also in response to serum addition. Furthermore, the increase in HIF-2α protein in the absence of SINHCAF is blunted in the absence of serum (Figure 2F). Taken together, our results are consistent with SINHCAF control of HIF-2α mRNA being observed also at the protein level of this important transcription factor.
SINHCAF regulates the HIF-2α promoter directly and is important for HDAC1 recruitment
Very little is known about the regulation of the HIF-2α gene, apart that it can be regulated by E2F1 [43], its promoter can be methylated [56,57], and that HDACs can repress both HIF-2α and HIF-1α genes [44]. We could also confirm that indeed depleting HDAC1 or treating cells with the class I and II HDAC inhibitor TSA resulted in increased levels of HIF-1α and HIF-2α, observed at mRNA (Figure 3A and B) and protein level (Figure 3C).
Analysis of published datasets revealed that the HIF-2α promoter was identified in an SIN3A ChIP-sequencing experiment (Figure 3D). To determine if the HIF-2α promoter was being specifically regulated by SINHCAF, we analyzed HIF-2α promoter constructs in the presence or absence of SINHCAF. HeLa and U2OS cells, stably expressing a renilla luciferase-HIF-2α promoter construct, were transfected with control or one of two SINHCAF siRNA oligonucleotides (Figure 3E). In accordance with our previous results investigating HIF-2α mRNA levels, SINHCAF knockdown resulted in a significant increase in renilla luciferase activity, suggesting that the HIF-2α promoter is regulated by SINHCAF. A decrease in promoter activity was also observed when SINHCAF was overexpressed (Supplementary Figure S2A).
To test if SINHCAF can control the HIF-2α promoter directly, ChIP for SINHCAF and qPCR analysis using primers directed toward the HIF-2α promoter was performed. This analysis revealed a significant enrichment of SINHCAF present at the HIF-2α promoter (Figure 3F). We had previously demonstrated that SINHCAF was required for HDAC1 recruitment to the Cyclin D1 promoter [1]. We thus determined if a similar mechanism was in place for the HIF-2α promoter. We analyzed the levels of HDAC1 and AcH3 in the presence or absence of SINHCAF (Figure 3G,H) present at the HIF-2α promoter. This analysis revealed that SINHCAF depletion resulted in a decrease in the levels of HDAC1 detected at the HIF-2α promoter (Figure 3G) with a correspondent increase in histone acetylation (Figure 3H), consistent with the proposed mechanism of SIN3A/HDAC1 recruitment to the HIF-2α promoter. Taken together, these results demonstrate that SINHCAF is important for HDAC1 recruitment to the HIF-2α promoter, controlling transcription of the HIF-2α gene.
SINHCAF represses HIF-2α promoter via SP1
The results obtained with HDAC inhibition suggest that SINHCAF provide the specificity of targeting a specific HIF-α isoform. Bioinformatic analysis of the HIF-2α promoter revealed potential binding sites for NF-κB, E2F1, and SP1 [43]. To determine the possible contribution of the predicted transcription factors to the control of HIF-2α expression, each factor was sequentially knocked down by siRNA in HeLa cells. We also included SP3, given its close overlap with SP1. The loss of SP3 was shown to reduce the basal expression of HIF-1α RNA with SP3 acting as an activator of basal HIF-1α RNA expression (Figure 4A and Supplementary Figure S3A). SP1, E2F1, and p52 were all shown to affect the basal expression of HIF-2α mRNA. Here, E2F1 and p52 function as activators, while SP1 functions as a repressor of basal HIF-2α mRNA expression (Figure 4A).
We next determined if any of these transcription factors was able to interact with SINHCAF. To this end, immunoprecipitation reactions were performed for SINHCAF and levels of the putative HIF-2α transcriptional regulators were investigated. SP1 and p52 were found to interact with SINHCAF in HeLa cells (Figure 4B). This result in combination with our previous published studies [1,48,58] suggests that SINHCAF might interact with p52 to control Cyclin D1 promoter. Based on the observation that only SP1 was able to repress the levels of HIF-2α mRNA, and was found to interact with SINHCAF in co-immunoprecipitation experiments, we hypothesized that SP1 is the transcription factor responsible for the recruitment of SINHCAF and the SIN3A–HDAC complex to the HIF-2α promoter. To test this hypothesis, control, SINHCAF, and SP1 were singly or doubly knocked down by siRNA in HeLa cells, with or without exposure to hypoxia for 24 h. Consistent with the mRNA analysis, none of the depletions resulted in a significant change in HIF-1α protein expression (Figure 4C). However, loss of SINHCAF or SP1 resulted in a significant increase in HIF-2α protein expression compared with control (Figure 4C). Interestingly, double depletion of SINHCAF and SP1 had similar effects to single knockdown approaches, suggesting that both proteins work in the same pathway. This was also confirmed by mRNA expression analysis through qPCR in HeLa cells. Single or combined loss of SINHCAF and SP1 resulted in a significant but non-additive increase in HIF-2α but not in HIF-1α mRNA expression (Figure 4D). These results suggest that both SINHCAF and SP1 act in the same pathway to repress HIF-2α.
Complex occupancy at the HIF-2α promoter
To test if SP1 can control the recruitment of SINHCAF to the HIF-2α promoter, ChIP was performed in HeLa cells, proficient or depleted of SP1. siRNA depletion of SP1 resulted in a significant reduction in SINHCAF promoter occupancy (Figure 5A). Interestingly, SP1 occupancy was similarly affected by SINHCAF knockdown (Figure 5B), suggesting an important interaction between these two factors. To determine if both proteins occupy the same site, ChIP/re-ChIP for SP1/SINHCAF was performed. This analysis demonstrated that both proteins do co-occupy the HIF-2α promoter (Figure 5C). We next investigated if SP1 is also important for the recruitment of HDAC1 to the HIF-2α promoter and the functional consequences of this. Levels of HDAC1 and AcH3 in the presence or absence of SP1 were analyzed (Figure 5D,E). This analysis revealed that SP1 depletion resulted in locally increased histone acetylation consistent with the decrease in HDAC1 recruitment to the HIF-2α promoter (Figure 5D,E). Taken together, these results demonstrate that SP1 is important for SINHCAF/HDAC1 recruitment to the HIF-2α promoter.
SINHCAF controls HIF-2α activity in cells
HIF transcription factors have important functions in tumor progression, such as controlling proliferation and angiogenesis [59–63]. To determine the importance of SINHCAF-mediated control of HIF-2α functions in cancer, in vitro cellular assays of angiogenesis were performed. Human umbilical vein endothelial cell (HUVEC) tube formation is analogous to angiogenesis in vivo. Conditioned media from DLD-1 tumor cells that had been treated with single or double siRNA knockdown of control, SINHCAF, and HIF-2α and treated with hypoxia for 24 h were collected. HUVECs were encouraged to form tubes in the presence of conditioned media for 24 h. The loss of SINHCAF resulted in a significant increase in total tube length following treatment with conditioned media, loss of HIF-2α resulted in a significant reduction in the same parameter, and combined depletion recovered the effects observed with individual SINHCAF and HIF-2α depletions (Figure 6A).
An important cellular function deregulated in cancer is proliferation. To determine how SINHCAF control over HIF-2α alters cell proliferation, HeLa and DLD-1 cells were transfected with control, SINHCAF, HIF-2α, or SINHCAF and HIF-2α siRNAs, and cell proliferation was analyzed using colony-forming assays. This analysis revealed that SINHCAF depletion resulted in a decreased number of colonies, while HIF-2α depletion significantly increased colony formation in both cell types (Figure 6B). Importantly, the effect of SINHCAF depletion on colony numbers was shown to be dependent on HIF-2α (Figure 6B and Supplementary Figure S4A), demonstrating the importance of SINHCAF control over HIF-2α levels and function.
To investigate the functional significance of SINHCAF depletion in additional biological responses, we performed a basic proliferation assay by counting the total cell number through time when cells possessed or not SINHCAF protein (Figure 6C). This analysis revealed that cell proliferation was significantly reduced 3 days following transfection of cells with SINHCAF siRNA oligonucleotides. To further determine the cause of these defects in proliferation and colony formation, we investigated levels of apoptosis (Figure 6D) and cell cycle distribution (Figure 6E). HeLa cells depleted of SINHCAF for 48 h revealed increased levels of apoptosis markers such as reduction caspase 3 levels, reduction of total PARP levels, and increased levels of cleaved PARP (Figure 6D). This was also observed in the percentage of cells present in the sub-G1 population detected in the flow cytometry analysis (Figure 6D, graphic). Markers for autophagy were slightly reduced, with decreased levels of LC3B, and increased levels of p62. These data suggest that reduction of SINHCAF results in reduction of cellular viability. Finally, cell cycle analysis revealed that SINHCAF depletion resulted in a modest but significant increase in cell arrested in the G2/M stage of the cell cycle (Figure 6E). Taken together, these results suggest that SINHCAF can control both cell cycle and cell death pathways.
Discussion
In the present study, we show that SINHCAF, a relatively unknown protein, controls the expression of the HIF-2α gene. We found that SINHCAF acts to epigenetically silence expression of the HIF-2α gene through recruitment of the SIN3–HDAC co-repressor factor. This complex regulates HIF-2α expression via its interaction with the transcription factor SP1. SINHCAF expression is linked to functional cellular changes in angiogenesis (tube formation), viability, proliferation, and cell cycle in vitro (Figure 6F).
Evidence is emerging to suggest that control of the basal expression of the HIF system is as important as its hypoxia-responsive post-translational degradation [64]. Changes in basal expression of the HIF-α isoforms are important in determining tissue-specific, hypoxia-inducible gene expression and are also important in the progression of multiple types of disease including cancer [30,34,35,64–68]. Basal HIF expression appears to be regulated by a transcriptional rheostat that is designed to allow an organism to respond in a heterogeneous manner to changes in oxygen supply and demand through space and time. The HIF system is set differently in different cells, in a manner that is appropriate for the physiological control of oxygen homeostasis [69]. Our own laboratory has demonstrated the importance of regulation of the expression of HIF-1α previously. We demonstrated that the ATP-dependent chromatin remodeling complex SWI/SNF directly affects both the expression of HIF 1α and its ability to transactivate target genes [68].
The specific nature of the mechanism involving SINHCAF would allow selective repression of HIF-2α. This proposed mechanism of transcriptional regulation by chromatin modification is one established mechanism for the heritable control of transcription that would be capable of specifically controlling the temporal and spatial transcription of HIF-2α, a phenomenon already seen in several cell types. SINHCAF repression was shown to be specific for HIF-2α, while HDAC1 repression is seen for both HIF-2α and HIF 1α. SINHCAF thus acts as a specificity factor for HDAC-mediated control of the HIF genes.
HIF-2α repression has been shown to be important for progression of the disease [70]. In vitro analysis of SINHCAF and HIF-2α regulated cellular responses demonstrated their co-dependency. Our results demonstrate that indeed, SINHCAF depletion prevents colony formation, while HIF-2α depletion induced a significant increase in colonies formed. Again, these responses were reversed upon co-depletion. Furthermore, SINHCAF was seen to repress tube formation via HIF-2α with total recovery achieved following co-depletion. This implies that SINHCAF depletion results in an increased quality of blood vessels, an important aspect required for tumor suppression [71]. In addition, we observed that cells depleted of SINHCAF arrest in the G2/M stage of the cell cycle. This is an intriguing observation, given that HIF-2α is known to co-operate with c-Myc to drive the cell cycle in hypoxic cells [72]. However, our results are set in a normoxic setting and suggest that cells are accumulating in G2/M possibly due to S-phase defects. This is consistent with our previous results where we could determine that cells depleted from SINHCAF progressed faster through S-phase [1]. However, a more detailed analysis of the SINHCAF-depleted cell, regarding replicative stress, would be required to fully investigate this possibility.
HIF-2α repression can drive tumor progression indirectly through loss of expression of HIF-2α-dependent tumor suppressors. In support of these proposals, HIF-2α, but not HIF-1α deletion, has been shown to increase tumor growth and progression secondary to loss of the tumor suppressor secretoglobin 3a1 protein in a KRAS-driven lung tumor model [73,74]. In addition, HIF-2α was proposed to act as a tumor suppressor in a glioma rat model [75]. However, HIF-2α functions are very cell type-specific, since it is clear it acts as a tumor promoter in renal cancer [76,77]. Furthermore, similar tissue specificity has been observed for HIF-1α, which acts as tumor suppressor in renal cancer [78], but as a tumor promoter in breast cancer [79]. Our findings with SINHCAF provide another possible mechanism by which HIF-1α and HIF-2α are differentially regulated, strongly suggesting that indeed, non-canonical mechanisms control the HIF system, confer tissue/cell specificity, and influence the mode of action for these transcription factors.
The mechanism for the epigenetic regulation of HIF-2α by SINHCAF described in this manuscript represents an exciting and potentially druggable future therapeutic target. In the physiological environment, these mechanisms may play a more important role in the tissue-specific expression and kinetic response of the HIF-α isoforms than is currently understood. Selective inhibition of a specific HIF-α isoform in the context of cancer is an attractive proposal because it would allow enhanced specificity and targeting of therapy. Appropriate focus on the development of small molecule inhibitors of SINHCAF would provide an important therapy to reverse the effects of this protein whose deregulation is implicated in multiple disease processes. It might also be useful in predicting which patients might respond to HDAC inhibitors, which are already developed but have received conflicting results in clinical trials [80].
Acknowledgements
We thank Professor John Rouse for providing reagents and critical reading of the manuscript.
Abbreviations
- AcH3
acetylated histone H3
- ChIP
chromatin immunoprecipitation
- HDAC
histone deacetylase
- HIF
hypoxia-inducible factor
- NF-κB
nuclear factor kappa B
- ODD
oxygen-dependent degradation
- PARP
poly-ADP ribose polymerase
- PHDs
prolyl hydroxylases
- SINHCAF
SIN3A and HDAC-associated factor
- siRNA
small interfering RNA
- SP1
specificity protein 1
- TSA
trichostatin A
- vHL
von Hippel– Lindau
Author Contribution
J.B. and S.R. initiated the project and analyzed the data. J.B., M.B., D.B., I.M., and S.R. performed experiments and additional biochemical analysis, and J.B. and S.R. wrote the manuscript.
Funding
J.B. was funded by a Cancer Research UK clinical fellowship. D.B. was funded by a PhD studentship from the Portuguese Science Foundation and Graduate Program in Areas of Basic and Applied Biology (GABBA). M.B. was funded by an MRC PhD studentship. S.R. was funded by a Cancer Research UK Senior Research Fellowship C99667/A12918. This work was also supported by a Wellcome Trust Strategic Award [097945/B/11/Z] and additionally supported by a small grant from the Anne and Normile Baxter prize for cancer research 2014.
Competing Interests
The Authors declare that there are no competing interests associated with the manuscript.
Supplementary Material
References
- 1.Muñoz I.M., MacArtney T., Sanchez-Pulido L., Ponting C.P., Rocha S. and Rouse J. (2012) Family with sequence similarity 60A (FAM60A) protein is a cell cycle-fluctuating regulator of the SIN3-HDAC1 histone deacetylase complex. J. Biol. Chem. 287, 32346–32353 10.1074/jbc.M112.382499 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Smith K.T., Sardiu M.E., Martin-Brown S.A., Seidel C., Mushegian A., Egidy R. et al. (2012) Human family with sequence similarity 60 member A (FAM60A) protein: a new subunit of the Sin3 deacetylase complex. Mol. Cell. Proteomics 11, 1815–1828 10.1074/mcp.M112.020255 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Saunders A., Huang X., Fidalgo M., Reimer M.H. Jr, Faiola F., Ding J. et al. (2017) The SIN3A/HDAC corepressor complex functionally cooperates with NANOG to promote pluripotency. Cell Rep. 18, 1713–1726 10.1016/j.celrep.2017.01.055 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Kadamb R., Mittal S., Bansal N., Batra H. and Saluja D. (2013) Sin3: insight into its transcription regulatory functions. Eur. J. Cell Biol. 92, 237–246 10.1016/j.ejcb.2013.09.001 [DOI] [PubMed] [Google Scholar]
- 5.Imamura M., Takahashi A., Yamauchi T., Hara K., Yasuda K., Grarup N. et al. (2016) Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes. Nat. Commun. 7, 10531 10.1038/ncomms10531 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Dong G., Mao Q., Yu D., Zhang Y., Qiu M., Dong G. et al. (2017) Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy. Sci. Rep. 7, 42060 10.1038/srep42060 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Streubel G., Fitzpatrick D.J., Oliviero G., Scelfo A., Moran B., Das S. et al. (2017) Fam60a defines a variant Sin3a-Hdac complex in embryonic stem cells required for self-renewal. EMBO J. 36, 2216–2232 10.15252/embj.201696307 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Moniz S., Biddlestone J. and Rocha S. (2014) Grow(2): the HIF system, energy homeostasis and the cell cycle. Histol. Histopathol. 29, 589–600 10.14670/HH-29.10.589 [DOI] [PubMed] [Google Scholar]
- 9.Schofield C.J. and Ratcliffe P.J. (2004) Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5, 343–354 10.1038/nrm1366 [DOI] [PubMed] [Google Scholar]
- 10.Rocha S. (2007) Gene regulation under low oxygen: holding your breath for transcription. Trends Biochem. Sci. 32, 389–397 10.1016/j.tibs.2007.06.005 [DOI] [PubMed] [Google Scholar]
- 11.Keith B. and Simon M.C. (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465–472 10.1016/j.cell.2007.04.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Semenza G.L. (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60, 591–597 10.1002/iub.93 [DOI] [PubMed] [Google Scholar]
- 13.Semenza G.L. (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207–214 10.1016/j.tips.2012.01.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wang G.L., Jiang B.H., Rue E.A. and Semenza G.L. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. U.S.A. 92, 5510–5514 10.1073/pnas.92.12.5510 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Carroll V.A. and Ashcroft M. (2006) Role of hypoxia-inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 66, 6264–6270 10.1158/0008-5472.CAN-05-2519 [DOI] [PubMed] [Google Scholar]
- 16.Hu C.-J., Iyer S., Sataur A., Covello K.L., Chodosh L.A. and Simon M.C. (2006) Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1α) and HIF-2α in stem cells. Mol. Cell. Biol. 26, 3514–3526 10.1128/MCB.26.9.3514-3526.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Patel S.A. and Simon M.C. (2008) Biology of hypoxia-inducible factor-2α in development and disease. Cell Death Differ. 15, 628–634 10.1038/cdd.2008.17 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Epstein A.C.R., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R. et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43–54 10.1016/S0092-8674(01)00507-4 [DOI] [PubMed] [Google Scholar]
- 19.Fandrey J., Gorr T.A. and Gassmann M. (2006) Regulating cellular oxygen sensing by hydroxylation. Cardiovasc. Res. 71, 642–651 10.1016/j.cardiores.2006.05.005 [DOI] [PubMed] [Google Scholar]
- 20.Bruegge K., Jelkmann W. and Metzen E. (2007) Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-α hydroxylases. Curr. Med. Chem. 14, 1853–1862 10.2174/092986707781058850 [DOI] [PubMed] [Google Scholar]
- 21.Frede S., Stockmann C., Freitag P. and Fandrey J. (2006) Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κB. Biochem. J. 396, 517–527 10.1042/BJ20051839 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M. et al. (2001) HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 10.1126/science.1059817 [DOI] [PubMed] [Google Scholar]
- 23.Jaakkola P., Mole D.R., Tian Y.-M., Wilson M.I., Gielbert J., Gaskell S.J. et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 10.1126/science.1059796 [DOI] [PubMed] [Google Scholar]
- 24.Yu F., White S.B., Zhao Q. and Lee F.S. (2001) HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl Acad. Sci. U.S.A. 98, 9630–9635 10.1073/pnas.181341498 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Pugh C.W., Tan C.C., Jones R.W. and Ratcliffe P.J. (1991) Functional analysis of an oxygen-regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc. Natl Acad. Sci. U.S.A. 88, 10553–10557 10.1073/pnas.88.23.10553 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Semenza G.L., Jiang B.-H., Leung S.W., Passantino R., Concordet J.-P., Maire P. et al. et al. (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271, 32529–32537 10.1074/jbc.271.51.32529 [DOI] [PubMed] [Google Scholar]
- 27.Schodel J., Oikonomopoulos S., Ragoussis J., Pugh C.W., Ratcliffe P.J. and Mole D.R. (2011) High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207–e217 10.1182/blood-2010-10-314427 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kaelin W.G. Jr and Ratcliffe P.J. (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30, 393–402 10.1016/j.molcel.2008.04.009 [DOI] [PubMed] [Google Scholar]
- 29.Kazi A.A., Gilani R.A., Schech A.J., Chumsri S., Sabnis G., Shah P. et al. (2014) Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Res. 16, R15 10.1186/bcr3609 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.van Uden P., Kenneth N.S. and Rocha S. (2008) Regulation of hypoxia-inducible factor-1α by NF-κB. Biochem. J. 412, 477–484 10.1042/BJ20080476 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V. et al. (2008) NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453, 807–811 10.1038/nature06905 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Belaiba R.S., Bonello S., Zahringer C., Schmidt S., Hess J., Kietzmann T. et al. et al. (2007) Hypoxia up-regulates hypoxia-inducible factor-1α transcription by involving phosphatidylinositol 3-kinase and nuclear factor κB in pulmonary artery smooth muscle cells. Mol. Biol. Cell 18, 4691–4697 10.1091/mbc.e07-04-0391 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Bonello S., Zahringer C., BelAiba R.S., Djordjevic T., Hess J., Michiels C. et al. (2007) Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site. Arterioscler. Thromb. Vasc. Biol. 27, 755–761 10.1161/01.ATV.0000258979.92828.bc [DOI] [PubMed] [Google Scholar]
- 34.van Uden P., Kenneth N.S., Webster R., Muller H.A., Mudie S. and Rocha S. (2011) Evolutionary conserved regulation of HIF-1β by NF-κB. PLoS Genet. 7, e1001285 10.1371/journal.pgen.1001285 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Bandarra D., Biddlestone J., Mudie S., Muller H.A. and Rocha S. (2014) Hypoxia activates IKK–NF-κB and the immune response in Drosophila melanogaster. Biosci. Rep. 34, 429–440 10.1042/BSR20140095 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Oh Y.T., Lee J.Y., Yoon H., Lee E.H., Baik H.H., Kim S.S. et al. (2008) Lipopolysaccharide induces hypoxia-inducible factor-1 alpha mRNA expression and activation via NADPH oxidase and Sp1-dependent pathway in BV2 murine microglial cells. Neurosci. Lett. 431, 155–160 10.1016/j.neulet.2007.11.033 [DOI] [PubMed] [Google Scholar]
- 37.Biswas S., Mukherjee R., Tapryal N., Singh A.K. and Mukhopadhyay C.K. (2013) Insulin regulates hypoxia-inducible factor-1α transcription by reactive oxygen species sensitive activation of Sp1 in 3T3-L1 preadipocyte. PLoS ONE 8, e62128 10.1371/journal.pone.0062128 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Lafleur V.N., Richard S. and Richard D.E. (2014) Transcriptional repression of hypoxia-inducible factor-1 (HIF-1) by the protein arginine methyltransferase PRMT1. Mol. Biol. Cell 25, 925–935 10.1091/mbc.e13-07-0423 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Patel N. and Kalra V.K. (2010) Placenta growth factor-induced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1α (HIF-1α) in endothelial cells. J. Biol. Chem. 285, 20570–20579 10.1074/jbc.M110.119495 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Niu G., Briggs J., Deng J., Ma Y., Lee H., Kortylewski M. et al. (2008) Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1α RNA expression in both tumor cells and tumor-associated myeloid cells. Mol. Cancer Res. 6, 1099–1105 10.1158/1541-7786.MCR-07-2177 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Koshikawa N., Hayashi J.-I., Nakagawara A. and Takenaga K. (2009) Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1α gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. J. Biol. Chem. 284, 33185–33194 10.1074/jbc.M109.054221 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Wada T., Shimba S. and Tezuka M. (2006) Transcriptional regulation of the hypoxia inducible factor-2α (HIF-2α) gene during adipose differentiation in 3T3-L1 cells. Biol. Pharm. Bull. 29, 49–54 10.1248/bpb.29.49 [DOI] [PubMed] [Google Scholar]
- 43.Moniz S., Bandarra D., Biddlestone J., Campbell K.J., Komander D., Bremm A. et al. (2015) Cezanne regulates E2F1-dependent HIF2α expression. J. Cell Sci. 128, 3082–3093 10.1242/jcs.168864 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Nakazawa M.S., Eisinger-Mathason T.S.K., Sadri N., Ochocki J.D., Gade T.P.F., Amin R.K. et al. (2016) Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Nat. Commun. 7, 10539 10.1038/ncomms10539 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Batie M., Druker J., D'Ignazio L. and Rocha S. (2017) KDM2 family members are regulated by HIF-1 in hypoxia. Cells 6, 8 10.3390/cells6010008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Culver C., Sundqvist A., Mudie S., Melvin A., Xirodimas D. and Rocha S. (2010) Mechanism of hypoxia-induced NF-κB. Mol. Cell Biol. 30, 4901–4921 10.1128/MCB.00409-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Kenneth N.S., Mudie S. and Rocha S. (2010) IKK and NF-κB-mediated regulation of Claspin impacts on ATR checkpoint function. EMBO J. 29, 2966–2978 10.1038/emboj.2010.171 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Schumm K., Rocha S., Caamano J. and Perkins N.D. (2006) Regulation of p53 tumour suppressor target gene expression by the p52 NF-κB subunit. EMBO J. 25, 4820–4832 10.1038/sj.emboj.7601343 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Culver C., Melvin A., Mudie S. and Rocha S. (2011) HIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs. Cell Cycle 10, 1249–1260 10.4161/cc.10.8.15326 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.ENCODE Project Consortium. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 10.1038/nature11247 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Sloan C.A., Chan E.T., Davidson J.M., Malladi V.S., Strattan J.S., Hitz B.C. et al. (2016) ENCODE data at the ENCODE portal. Nucleic Acids Res. 44, D726–D732 10.1093/nar/gkv1160 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Hahne F. and Ivanek R. (2016) Visualizing genomic data using Gviz and bioconductor. Methods Mol. Biol. 1418, 335–351 10.1007/978-1-4939-3578-9_16 [DOI] [PubMed] [Google Scholar]
- 53.Bandarra D., Biddlestone J., Mudie S., Müller H.-A.J. and Rocha S. (2015) HIF-1α restricts NF-κB-dependent gene expression to control innate immunity signals. Dis. Model. Mech. 8, 169–181 10.1242/dmm.017285 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Ortmann B., Bensaddek D., Carvalhal S., Moser S.C., Mudie S., Griffis E.R. et al. (2016) CDK-dependent phosphorylation of PHD1 on serine 130 alters its substrate preference in cells. J. Cell Sci. 129, 191–205 10.1242/jcs.179911 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Kenneth N.S., Mudie S., Naron S. and Rocha S. (2013) Tfr1 interacts with the IKK complex and is involved in IKK–NF-κB signalling. Biochem. J. 449, 275–284 10.1042/BJ20120625 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Cui J., Duan B., Zhao X., Chen Y., Sun S., Deng W. et al. (2016) MBD3 mediates epigenetic regulation on EPAS1 promoter in cancer. Tumour. Biol. 37, 13455–13467 10.1007/s13277-016-5237-1 [DOI] [PubMed] [Google Scholar]
- 57.Cruzeiro G.A.V., Dos Reis M.B., Silveira V.S., Lira R.C.P., Carlotti C.G. Jr, Neder L. et al. (2018) HIF1A is overexpressed in medulloblastoma and its inhibition reduces proliferation and increases EPAS1 and ATG16L1 methylation. Curr. Cancer Drug. Targets 18, 287–294 10.2174/1568009617666170315162525 [DOI] [PubMed] [Google Scholar]
- 58.Rocha S., Martin A.M., Meek D.W. and Perkins N.D. (2003) P53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol. Cell. Biol. 23, 4713–4727 10.1128/MCB.23.13.4713-4727.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E. et al. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10, 858–864 10.1038/nm1075 [DOI] [PubMed] [Google Scholar]
- 60.Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A. and Simon M.C. (1997) Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386, 403–407 10.1038/386403a0 [DOI] [PubMed] [Google Scholar]
- 61.Semenza G.L. (2009) Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology 24, 97–106 10.1152/physiol.00045.2008 [DOI] [PubMed] [Google Scholar]
- 62.Koshiji M., Kageyama Y., Pete E.A., Horikawa I., Barrett J.C. and Huang L.E. (2004) HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23, 1949–1956 10.1038/sj.emboj.7600196 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Gordan J.D., Thompson C.B. and Simon M.C. (2007) HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12, 108–113 10.1016/j.ccr.2007.07.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Kuschel A., Simon P. and Tug S. (2012) Functional regulation of HIF-1α under normoxia—is there more than post-translational regulation? J. Cell Physiol. 227, 514–524 10.1002/jcp.22798 [DOI] [PubMed] [Google Scholar]
- 65.Pagé E.L., Robitaille G.A., Pouysségur J. and Richard D.E. (2002) Induction of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. J. Biol. Chem. 277, 48403–48409 10.1074/jbc.M209114200 [DOI] [PubMed] [Google Scholar]
- 66.Blouin C.C., Pagé E.L., Soucy G.M. and Richard D.E. (2004) Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1α. Blood 103, 1124–1130 10.1182/blood-2003-07-2427 [DOI] [PubMed] [Google Scholar]
- 67.Gorlach A. (2009) Regulation of HIF-1α at the transcriptional level. Curr. Pharm. Des. 15, 3844–3852 10.2174/138161209789649420 [DOI] [PubMed] [Google Scholar]
- 68.Kenneth N.S., Mudie S., van Uden P. and Rocha S. (2009) SWI/SNF regulates the cellular response to hypoxia. J. Biol. Chem. 284, 4123–4131 10.1074/jbc.M808491200 [DOI] [PubMed] [Google Scholar]
- 69.Rosenberger C., Mandriota S., Jurgensen J.S., Wiesener M.S., Horstrup J.H., Frei U. et al. (2002) Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys. J. Am. Soc. Nephrol. 13, 1721–1732 10.1097/01.ASN.0000017223.49823.2A [DOI] [PubMed] [Google Scholar]
- 70.Rawłuszko-Wieczorek A.A., Horbacka K., Krokowicz P., Misztal M. and Jagodziński P.P. (2014) Prognostic potential of DNA methylation and transcript levels of HIF1A and EPAS1 in colorectal cancer. Mol. Cancer Res. 12, 1112–1127 10.1158/1541-7786.MCR-14-0054 [DOI] [PubMed] [Google Scholar]
- 71.Semenza G.L. (2013) Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis and metastasis. Oncogene 32, 4057–4063 10.1038/onc.2012.578 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Gordan J.D., Bertout J.A., Hu C.-J., Diehl J.A. and Simon M.C. (2007) HIF-2α promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell 11, 335–347 10.1016/j.ccr.2007.02.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Mazumdar J., Hickey M.M., Pant D.K., Durham A.C., Sweet-Cordero A., Vachani A. et al. (2010) HIF-2α deletion promotes Kras-driven lung tumor development. Proc. Natl Acad. Sci. U.S.A. 107, 14182–14187 10.1073/pnas.1001296107 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Krop I., Parker M.T., Bloushtain-Qimron N., Porter D., Gelman R., Sasaki H. et al. (2005) HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res. 65, 9659–9669 10.1158/0008-5472.CAN-05-1663 [DOI] [PubMed] [Google Scholar]
- 75.Acker T., Diez-Juan A., Aragones J., Tjwa M., Brusselmans K., Moons L. et al. (2005) Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8, 131–141 10.1016/j.ccr.2005.07.003 [DOI] [PubMed] [Google Scholar]
- 76.Cho H. and Kaelin W.G. (2016) Targeting HIF2 in clear cell renal cell carcinoma. Cold Spring Harb. Symp. Quant. Biol. 81, 113–121 10.1101/sqb.2016.81.030833 [DOI] [PubMed] [Google Scholar]
- 77.Chen W., Hill H., Christie A., Kim M.S., Holloman E., Pavia-Jimenez A. et al. (2016) Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112–117 10.1038/nature19796 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Shen C., Beroukhim R., Schumacher S.E., Zhou J., Chang M., Signoretti S. et al. (2011) Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov. 1, 222–235 10.1158/2159-8290.CD-11-0098 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Semenza G.L. (2016) The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim. Biophys. Acta, Mol. Cell Res. 1863, 382–391 10.1016/j.bbamcr.2015.05.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Nervi C., De Marinis E. and Codacci-Pisanelli G. (2015) Epigenetic treatment of solid tumours: a review of clinical trials. Clin. Epigenetics 7, 127 10.1186/s13148-015-0157-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.